High Syk-n expression indicated a better overall survival among platinum-resistant patients (P = 0.001, Fig. 3a), patients with tumours confined to the ovaries (stage 1 ovarian cancer) (P = 0.001, Fig. 3b) and patients with no residual disease (P = 0.001) (Fig. 3c). The gene discussed is SYK; the disease is ovarian carcinoma.